Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Scimed/Organogenesis

This article was originally published in The Gray Sheet

Executive Summary

Scimed/Organogenesis: Sign letter of intent to develop and commercialize collagen-coated endovascular stents for treatment of ischemic heart disease and peripheral vascular disease. The stents will "combine Organogenesis' collagen technologies with Scimed stent and catheter technologies," Organogenesis says. The non-thrombogenic nature of the collagen coating would give the stents "significant benefits not available" in currently marketed devices, according to the company. Under terms of the deal, Scimed would pay Organogenesis $11 mil. in upfront and milestone payments, as well as royalties and manufacturing payments. Scimed also would fund both companies' research and development efforts in this area...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts